Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration

British Journal of Clinical Pharmacology

Volumn 54, Issue 6, 2002, Pages 635-642

  Ogutu, Bernhards R ^a,b   Newton, Charles R J C ^a,c   Muchohi, Simon N ^a   Otieno, Godfrey O ^a   Kokwaro, Gilbert O ^a,b  

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Children; Chloramphenicol; Fosphenytoin; Interaction; Malaria; Pharmacokinetics; Phenytoin

Indexed keywords

CEFOTAXIME; CHLORAMPHENICOL; FOSPHENYTOIN SODIUM;

AFRICA; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; BREATHING RATE; CARDIOVASCULAR PARAMETERS; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSCIOUSNESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEART RATE; HUMAN; INFANT; MALARIA; MALE; OXYGEN SATURATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTI-BACTERIAL AGENTS; ANTICONVULSANTS; AREA UNDER CURVE; CEFOTAXIME; CHILD, PRESCHOOL; CHLORAMPHENICOL; DRUG THERAPY, COMBINATION; FEMALE; HALF-LIFE; HUMANS; INFANT; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MALARIA; MALE; MODELS, BIOLOGICAL; PHENYTOIN; SEIZURES;

EID: 0036902665     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.2002.01689.x     Document Type: Article

References (53)

1. Warrell D, Molyneux M, Beales P. Severe and complicated malaria. Trans R Soc Trop Med Hyg 1990; 84 (Suppl 2): 1-65.
2. Molyneux ME, Taylor TE, Wirima JJ, Borgstein A. Clinical features and prognostic indicators in paediatric cerebral malaria: A study of 131 comatose Malawian children. Q J Med 1989; 71: 441-459.
3. Waruiru CM, Newton CRJC, Forster D, et al. Epileptic seizures and malaria in Kenyan children. Trans R Soc Trop Med Hyg 1996; 90: 152-155.
4. Wattanagoon Y, Srivilairit S, Looareesuwan S, White NJ. Convulsions in childhood malaria. Trans R Soc Trop Med Hyg 1994; 88: 426-428.
5. Crawley J, Smith S, Kirkham F, Muthinji P, Waruiru C, Marsh K. Seizures and status epilepticus in childhood cerebral malaria. Q J Med 1996; 89: 591-597.
6. Ogutu BR, Newton CRJC, Crawley J, et al. Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions. Br J Clin Pharmacol 2002; 53: 49-57.
7. Berkley JA, Mwangi I, Ngetsa CJ, et al. Diagnosis of acute bacterial meningitis in children at a district hospital in sub-Saharan Africa. Lancet 2001; 357: 1753-1757.
8. Berkley J, Mwarumba S, Bramham K, Lowe B, Marsh K. Bacteraemia complicating severe malaria in children. Trans R Soc Trop Med Hyg 1999; 93: 283-286.
9. Berkley JA, Mwangi I, Mellington F, Mwarumba S, Marsh K. Cerebral malaria versus bacterial meningitis in children with impaired consciousness. Q J Med 1999; 92: 151-157.
10. Wright PW, Avery WG, Ardill WD, McLarty JW. Initial clinical assessment of the comatose patient: Cerebral malaria versus meningitis. Pediatr Inf Dis J 1993; 12: 37-41.
11. Newton CRJC, Kirkham FJ, Winstanley PA, et al. Intracranial pressure in African children with cerebral malaria. Lancet 1991; 337: 573-576.
12. Newton CJRC, Krishna S. Severe falciparum malaria in children: Current understanding of pathophysiology and supportive treatment. Pharmacol Ther 1998; 79: 1-53.
13. Holding PA, Stevenson J, Peshu N, Marsh K. Cognitive sequelae of severe malaria with impaired consciousness. Trans R Soc Trop Med Hyg 1999; 93: 529-534.
14. Crawley J, Waruiru C, Mithwani S, et al. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: A randomised controlled intervention study. Lancet 2000; 355: 701-706.
15. Ogutu BR, Newton CRJC, Muchohi SN, et al. Pharmacokinetics and clinical effects of phenytoin in children with malaria and convulsions. Br J Clin Pharmacol (in press).
16. Christensen LK, Skovsted L. Inhibition of drug metabolism by chloramphenicol. Lancet 1969; ii: 1397-1399.
17. Ballek RE, Reidenberg MM, Orr L. Inhibition of diphenylhydantoin metabolism by chloramphenicol. Lancet 1973; i: 150.
18. Koup JR, Gibaldi M, McNamara P, Hilligoss DM, Colburn WA, Bruck E. Interaction of chloramphenicol with phenytoin and phenobarbital: Case report. Clin Pharmacol Ther 1978; 24: 571-575.
19. Greenlaw CW. Chloramphenicol-phenytoin interaction. Drug Intell Clin Pharm 1979; 13: 609-610.
20. Salter M, Stephens NM. Phenytoin-chloramphenicol interaction. Drug Intell Clin Pharm 1980; 14: 221.
21. Landesman SH, Corrado MS, Shah PM, et al. Past and current roles of cephalosporin antibiotics in the treatment of meningitis. Am J Med 1981; 71: 693-703.
22. Dasgupta A, Dennen DA, Dean R, McLawhon RW. Displacement of phenytoin from serum protein carriers by antibiotics: Studies with ceftriaxone, nafcillin, and sulfamethoxazole. Clin Chem 1991; 37: 98-100.
23. Cwik MJ, Liang M, Deyo K, Andrews C, Fischer J. Simultaneous rapid high-performance liquid chromatographic determination of phenytoin and its pro-drug fosphenytoin in human plasma and ultrafiltrate. J Chromatogr 1997; 693: 407-414.
24. Aynacioglu AS, Brockmoller J, Bauer S, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol 1999; 48: 409-415.
25. Velagapudi R, Smith RV, Ludden T, Sagraves R. Simultaneous determination of chloramphenicol and chloramphenicol succinate in plasma using high performance liquid chromatography. J Chromatogr 1982; 228: 423-428.
26. Drewe J, Ball HA, Beglinger C, et al. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br J Clin Pharmacol 2000; 50: 237-246.
27. Heinzel G, Degner B. Pharmacokinetic fitting of data exhibiting nonlinear (Michaelis-Menten) kinetics. In Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC, eds Heinzel, G, Woloszczak, R, Thomann, P. Stuttgart: Gustav Fischer, 1993; 5.101-5.102.
28. Akaike A. Posterior probabilities for choosing a regression model. Annal Instit Math Stat 1978; 30: A9.
29. Heinzel G, Woloszczak R, Thomann P, eds. TopFit Version 2.0. Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Stuttgart: Gustav Fischer, 1993; 3.72-3.86.
30. Altman DG, Machin D, Bryant TN, Gardner MJ. Statistics with Confidence, 2nd Edn. Bristol, BMJ Books 2000, 15-27.
31. Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995; 332: 1399-1404.
32. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications, 2nd Edn. Philadelphia: Lea & Febiger 1989, 115.
33. Koran G, Barzilay Z, Schachar E, et al. Kinetics of CSF phenytoin in children. Can J Neurol Sci 1983; 10: 195-197.
34. Wagner JG. Pharmacokinetics for the Pharmaceutical Scientist, 1st Edn. Lancaster, Pennsylvania: Technomic Publishing Co., 1993, 128-129.
35. Jusko WG, Koup JR, Alvan G. Nonlinear assessment of phenytoin bioavailability. J Pharmacokin Biopharm 1976; 4: 327-336.
36. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin. Clin Pharmacokinet 1990; 18: 37-60.
37. Glazko AJ. Antiepileptic drugs: Biotransformation, metabolism, and serum half-life. Epilepsia 1975; 16: 367-391.
38. Witkin KM, Bius DL, Teague BL, et al. Determination of 5-(hydroxyphenyl)-5-phenylhydantoin and studies relating to the disposition of phenytoin in man. Ther Drug Monit 1979; 1: 11-34.
39. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications, 2nd Edn. Philadelphia: Lea & Febiger 1989, 154.
40. Powell JR, Cate EW. Induction and inhibition of drug metabolism. In Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, eds Evans WE, Schentag JJ, Jusko WJ. Applied Therapeutics Inc: Spokane WA. 1986; 139-186.
41. Hansen JM, Kampmann JP, Siersbaek-Nielsen K, et al. The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand 1979; 624 (Suppl): 106-110.
42. Veronese ME, Doecke CJ, Mackenzie PI, et al. Site-directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP2C subfamily. Biochem J 1993; 289: 533-538.
43. Doecke CJ, Veronese ME, Pond SM, et al. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 1991; 31: 125-130.
44. Zhang H, Coville PF, Walker RJ, et al. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine. Br J Clin Pharmacol 1997; 43: 245-252.
45. Dodson WE. Nonlinear kinetics of phenytoin in children. Neurology 1982; 32: 42-48.
46. Buchanan RA, Heffelfinger JC, Weiss CF. The effect of phenobarbital on diphenylhydantoin metabolism in children. Paediatrics 1969; 43: 114-116.
47. Garretson LK, Dayton PG. Disappearance of phenobarbital and diphenylhydantoin from serum of children. Clin Pharmacol Ther 1970; 11: 674-679.
48. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CYP2C9-Leu 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-349.
49. Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 4: 39-42.
50. Nimomiya H, Mamiya K, Matsuo S, et al. Genetic polymorphism of CYP2C subfamily and excessive serum phenytoin concentration with nervous system intoxication. Ther Drug Monit 2000; 22: 230-232.
51. Goldsten JA. Clinical relevance of genetic polymorphism in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-355.
52. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P4502C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001; 52: 447-450.
53. Halpert JR, Miller NE, Gorsky LD. On the mechanism of the inactivation of the major phenobarbital-induced isoenzyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem 1985; 260: 8397-8403.